BARBARA NJUGUNA: Open Payments
NPI 1235638230 · NUTLEY, NJ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$617 in 36 payments from 10 companies in 2025. Trend: 2023 $588 · 2024 $486 · 2025 $617
Food & beverage: $617
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 10 | $163 |
| Otsuka America Pharmaceutical, Inc. | 5 | $85 |
| Teva Pharmaceuticals USA, Inc. | 4 | $73 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $65 |
| Alkermes, Inc. | 3 | $57 |
| Bausch Health US, LLC | 3 | $52 |
| Axsome Therapeutics, Inc. | 3 | $51 |
| Neurocrine BioSciences, Inc. | 2 | $43 |
| E.R. Squibb & Sons, L.L.C. | 1 | $16 |
| Supernus Pharmaceuticals, Inc. | 1 | $14 |
Products named: VRAYLAR, REXULTI, CAPLYTA, Auvelity, UZEDY, INGREZZA, WELLBUTRIN, ARISTADA.
Industry payments across NJ — which companies pay providers there.
